Sensus Healthcare

SRTS · NASDAQ

$2.75−$0.01 (−0.36%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.76

SRTS analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $5.48 (+99.4% upside)

Low: $4.04
Now: $2.75
High: $6.30

Upgrades and downgrades

The latest rating actions, newest first

SRTS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Lake Street	Aug 14, 2026	Maintains	Buy	$4.50 → $4.00	41%
Maxim Group	Feb 17, 2026	Maintains	Buy	$8.00 → $6.00	26%

The case for and against

Updated May 8, 2025

Bull case

Sensus Healthcare Inc. demonstrated significant growth in its shipping operations, delivering 27 SRT systems in 3Q24, a notable increase from previous quarters, highlighting the company's expanding market reach and demand. The company's financial performance for FY2024 was strong, with total revenue of $41.8 million, reflecting a remarkable 71% year-over-year growth, coupled with a net income of $6.6 million, further reinforcing its solid financial position. Additionally, the successful signing of multiple Fair Deal Agreements, including one with a network of over 130 dermatology clinics, emphasizes the company's strategic initiatives poised to enhance revenue streams and solidify its foothold in the market.

Bear case

Sensus Healthcare faces significant investment risks that could hinder its financial performance, particularly concerning the commercial success of its SRT and TransDermalInfusion systems. The company's ability to penetrate the market successfully is threatened by potential reimbursement issues and increased competition in the health technology sector. Additionally, there is a risk of dilution which may negatively impact shareholder value and overall financial stability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.